I’m sure you have seen Mounjaro referred to in almost every single discussion regarding weight loss drugs as being in the same category as Ozempic, Wegovy, and Zepbound. But is Mounjaro indeed a GLP-1 drug? And in what way does it differ from the rest of the drugs in its same category? Well, the answer is not as easy as a simple “yes” or “no,” and you must understand it before you bring it up with your doctor.
For more trusted information on GLP-1 drugs and weight loss, visit glpweightloss.online.
Is Mounjaro a GLP-1?
Yes, Mounjaro is a GLP-1 drug. However, the more accurate answer would be to say that Mounjaro is a dual GIP and GLP-1 receptor agonist. This is because, unlike other medications in the same class, Mounjaro works by activating two different pathways within the body, rather than just one.
The active pharmaceutical ingredient in Mounjaro is a drug called tirzepatide. Tirzepatide is a single molecule that has been specifically designed to target and activate both the GIP and GLP-1 receptors. Mounjaro was developed by a pharmaceutical company called Eli Lilly and Company and was approved by the FDA in May 2022. This makes Mounjaro the first and only FDA-approved GIP and GLP-1 dual receptor agonist.
So while Mounjaro is indeed a GLP-1 drug, the more accurate description would be to say that Mounjaro is a next-generation GLP-1 and GIP drug.
What Is Mounjaro FDA-Approved For?
This is important – and is often the source of confusion. Mounjaro is FDA-approved for the improvement of blood sugar control in adults and children aged 10 years and above with type 2 diabetes, in addition to diet and exercise.
Mounjaro is NOT FDA-approved for weight loss. Any weight loss seen in the studies is considered a secondary endpoint of type 2 diabetes treatment, not the primary purpose.
If weight loss is what you want, the right medication is Zepbound, which is the obesity-approved version of the same medication (same active ingredient). Mounjaro and Zepbound contain the same active ingredient, but have different FDA indications, different insurance categories, and, in reality, different prescribing recommendations based on your diagnosis.
While Mounjaro can be prescribed off-label for weight loss, which is legal, insurance plans are very specific about this. A claim for Mounjaro with an obesity diagnosis code – as opposed to type 2 diabetes – is often denied.
Mounjaro vs. Zepbound – The Key Distinction
| Feature | Mounjaro | Zepbound |
| Active Ingredient | Tirzepatide | Tirzepatide |
| FDA-Approved For | Type 2 Diabetes | Chronic Weight Management & Obstructive Sleep Apnea |
| Same Molecule? | Yes (Identical chemical formulation) | Yes (Identical chemical formulation) |
| Insurance Category | Diabetes Benefit (standard Part D/Commercial) | Weight Loss Benefit (often requires specific riders) |
| Pediatric Approval | Yes (Ages 10+ for Type 2 Diabetes) | No (Currently approved for Adults 18+ only) |
The easiest way to think about it: Mounjaro and Zepbound are the same medication in different labeled packaging for different medical uses. Your doctor will prescribe one or the other based on your diagnosis and treatment needs.
How Does Mounjaro Work?
Tirzepatide works on two different hormonal pathways because it activates both GLP-1 and GIP receptors.
The GLP-1 pathway increases insulin in response to meals, decreases the glucose-raising hormone glucagon, slows the emptying of the stomach, and sends fullness signals to the brain.
The GIP pathway increases insulin and increases insulin sensitivity, and has an effect on appetite reduction through additional brain receptors. In addition, the receptors for GIP are found in fat cells, so tirzepatide has metabolic effects on fat tissue, which GLP-1 drugs do not.
The result of these two pathways is better control of blood sugars in type 2 diabetics, and as a bonus effect, substantial weight loss in these patients, which is typically greater than the weight loss achieved with GLP-1 drugs.
How Effective Is Mounjaro for Blood Sugar and Weight?
The clinical efficacy of Mounjaro in the SURPASS phase 3 clinical trials was outstanding.
For glucose control, Mounjaro resulted in reductions in HbA1c, which is an indication of the three-month average blood sugar levels, by as much as 2.3 percent. This is better than semaglutide at every dose in the head-to-head SURPASS 2 clinical trial.
For weight loss, although not its primary indication, Mounjaro resulted in 12-25 pounds in the SURPASS clinical trials, depending on the dose, compared to negligible changes in the placebo and comparator groups.
When Mounjaro was head-to-head against semaglutide for weight loss in the SURMOUNT 5 clinical trial for the Zepbound indication, Mounjaro resulted in 47 percent more relative weight loss, 20.2 percent versus 13.7 percent of body weight, because it is a dual-action medication and thus performs better than single-action GLP-1 receptor agonists.
Mounjaro vs. Ozempic and Wegovy
Since all three names get used interchangeably in everyday conversation, here’s a clear comparison:
| Feature | Mounjaro | Wegovy | Ozempic |
| Active Ingredient | Tirzepatide | Semaglutide | Semaglutide |
| Receptor Targets | GLP-1 + GIP (Dual Agonist) | GLP-1 Only | GLP-1 Only |
| FDA-Approved For | Type 2 Diabetes | Chronic Weight Management | Type 2 Diabetes |
| Weight Loss Results | ~12–25 lbs (Diabetes-specific trials) | ~15% Body Weight (up to 21% on HD) | ~5–10% Body Weight |
| Weekly Injection | Yes | Yes | Yes |
| Available as a pill | No (Injectable Only) | Yes (Wegovy Pill approved Dec 2025) | No (Rybelsus is the T2D oral version) |
The basic difference: Both Ozempic and Wegovy are single-receptor GLP-1 agonists utilizing semaglutide. Mounjaro and its weight loss counterpart Zepbound utilize tirzepatide, activating both GLP-1 and GIP receptors for enhanced metabolic effects across the board.
Side Effects of Mounjaro
The side effect profile is similar to the GLP-1 receptor agonist group. The common side effects include gastrointestinal problems like nausea, vomiting, diarrhea, constipation, abdominal pain, and loss of appetite. These will be more pronounced during the dose escalation phase. These will be reduced over time as the body adapts to the medication.
The dose escalation begins with 2.5mg per week and gradually increases over time to a maximum of 15mg per week. This slowing-down approach is the key to managing the tolerability issues.
The major but rare adverse effects include pancreatitis, gallbladder disease, renal impairment due to dehydration, and hypoglycemia with the use of insulin and insulin secretagogues. Mounjaro has a boxed warning regarding thyroid C-cell tumors based on animal studies. It is contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome of Type 2 (MEN2).
Mounjaro is not to be used during pregnancy. It is not to be used with other products that have tirzepatide or GLP-1 receptor agonist drugs.
Who Is Mounjaro Appropriate For?
The FDA has approved Mounjaro for adults and children 10 years and older with type 2 diabetes. This is a great option for you if you want to control your blood sugar levels. This is especially true if you have not seen satisfactory results from other drugs used for treating diabetes. It is also a great option if you want to control your blood sugar and weight at the same time.
If you have type 2 diabetes and want to use tirzepatide, then Mounjaro is the drug you will be prescribed. If you want to use tirzepatide but you don’t have type 2 diabetes, and you want to control your weight, then Zepbound is the drug you will be prescribed.
The Mounjaro drug is not suitable for people with type 1 diabetes, pregnant women, breastfeeding women, and people with a history of medullary thyroid cancer, MEN2, and pancreatitis. Your doctor will look at all these issues before making a decision regarding the medication you will use. For more information regarding the comparison of tirzepatide, semaglutide, and all other GLP-1 drugs for weight loss, please visit glpweightloss.online.
Frequently Asked Questions
Is Mounjaro a GLP-1 medication?
Yes — Mounjaro is a GLP-1 receptor agonist. More specifically, Mounjaro is a dual GIP and GLP-1 receptor agonist, activating two hormonal pathways simultaneously. This is what sets it apart from other GLP-1 receptor agonists like Ozempic and Wegovy, which activate only one pathway.
Is Mounjaro approved for weight loss?
No. Mounjaro is approved by the FDA to be used to manage type 2 diabetes. While weight loss is a significant side effect, this is not why it is approved by the FDA. If you are looking to lose weight, then the appropriate FDA-approved drug to discuss with your doctor is Zepbound, which is the same active ingredient but approved to be used to help with chronic weight management and obstructive sleep apnea.
What is the difference between Mounjaro and Zepbound?
They are the same medication, the same active ingredient, made by the same company, Eli Lilly. They are different, however, in their approved use. Mounjaro is approved to be used to help with type 2 diabetes. Zepbound is approved to be used to help with chronic weight management and obstructive sleep apnea.
Is Mounjaro better than Ozempic?
Clinically, yes; tirzepatide beats semaglutide in both blood sugar control and weight loss in every study where the two were compared. In the study where the two were compared in the weight loss arena, the weight loss was 47 percent greater with tirzepatide in the SURMOUNT-5 study. About blood sugar control, it beats semaglutide at every dose.
Can I use Mounjaro for weight loss if I don’t have diabetes?
Doctors can prescribe it off-label, but it will not be covered by insurance with an obesity diagnosis code only. If you do not have type 2 diabetes and wish to obtain the medication for weight loss, the way to go is to ask your physician about the FDA-approved version of the medication, Zepbound.
How much does Mounjaro cost?
Without insurance, the cost of Mounjaro is between $1,000 and $1,100 per month. If you have type 2 diabetes and insurance that will cover the medication, the copay can be significantly lower. Eli Lilly has a savings card program in place for those who qualify. If you have Medicare, programs expanding GLP-1 availability will be launched in mid-2026.
Resources
https://ro.co/weight-loss/difference-zepbound-mounjaro-ozempic-wegovy/
https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
https://www.medicalnewstoday.com/articles/how-much-is-mounjaro-without-insurance
https://www.boltpharmacy.co.uk/guide/is-mounjaro-a-glp-1
https://www.doctronic.ai/blog/ozempic-vs-wegovy-vs-mounjaro-vs-zepbound-which-works-best/
https://www.eurekahealth.com/resources/is-mounjaro-a-glp-1-or-something-different-en
